Spectrofluorimetric Determination Method for Pregabalin in Dosage Forms Using 9-Fluorenylmethyl Chloroformate Spectrofluorimetric determination of pregabalin
Iranian Journal of Pharmaceutical Sciences,
دوره 19 شماره 4 (2023),
24 April 2024
,
صفحه 350-359
https://doi.org/10.22037/ijps.v19i4.43503
چکیده
The present study produces a new, accurate, and simple spectrofluorimetric technique for the determination of pregabalin after derivatization with 9-fluorenylmethyl chloroformate in mild basic medium. Pregabalin, containing a primary amine group, reacts with 9-fluorenylmethyl chloroformate, a fluorophore reagent, in borate buffer and produces a fluorescent derivative. The maximum fluorescence intensity of the derivative and reagent was obtained at 315 nm after excitation at 280 nm. The fluorescence intensity of the reagent increases after derivatization with pregabalin, and the difference in the fluorescence intensity is proportional to the concentration of pregabalin. Experimental parameters which affect the derivatization reaction were studied. The best derivatization reaction between pregabalin and 9-fluorenylmethyl chloroformate was obtained after 30 sec. when 40 µg mL-1 of the reagent was used in a borate buffer of pH 9.0. Under optimized conditions, the linearity range (6-150 µg mL-1) of the method with a correlation coefficient of r2 0.9998, accuracy (Error<1.7%), and precision (CV<2.0%) was acceptable. The validated method was utilized for quantifying pregabalin in dosage form without interferences and showed good agreement with a reference method.
- pregabalin
- 9-fluorenylmethyl chloroformate
- derivatization
- spectrofluorimetry
- determination
- dosage form
ارجاع به مقاله
مراجع
Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin. Drug Metab. Toxicol. (2013) 9 (1): 105-15.
Rashid M, Sarfraz M, Arfat M, Hussain A, Abbas N, Hussain K, et al. Prediction of pharmacokinetic parameters and dose of pregabalin gastroretentive formulation in healthy adults, healthy pediatrics and renal-impaired geriatrics. J. Drug Deliv. Sci. Technol. (2021) 63: 102548.
Bockbrader HN, Burger P, Knapp L, Corrigan BW. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. (2011) 52 (2): 248-57.
Rogawski MA, Taylor CP. Calcium channel α2–δ subunit, a new antiepileptic drug target. J. Epilepsy Res. (2006) 69 (3): 183.
Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc). (2005) 41 (8): 509-16.
Zareba G. New treatment options in the management of fibromyalgia: role of pregabalin. Neuropsychiatr Dis Treat. (2008) 4 (6): 1193.
Frampton JE, Foster RH. Pregabalin. Drugs. (2005) 65 (1): 111-8.
Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. Cochrane Database Syst. Rev. (2019) 1.
Hong JS, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. J. Mol. Psychiatry. (2022) 27 (3): 1339-49.
Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. (2006) 6 (1): 108-13.
Micó J-A, Prieto R. Elucidating the mechanism of action of pregabalin. CNS drugs. (2012) 26 (8): 637-48.
Pan Y, Davis PB, Kaebler DC, Blankfield RP, Xu R. Cardiovascular risk of gabapentin and pregabalin in patients with diabetic neuropathy. Cardiovasc. Diabetol. (2022) 21 (1): 170.
Servais L, Huberland V, Richelle L. Misuse of Pregabalin: a qualitative study from a patient’s perspective. BMC public health. (2023) 23 (1): 1339.
Vaidya VV, Yetal SM, Roy S, Gomes NA, Joshi SS. LC-MS–MS Determination of pregabalin in human plasma. Chromatographia. (2007) 66 (11): 925-8.
Mandal U, Sarkar AK, Gowda KV, Agarwal S, Bose A, Bhaumik U, et al. Determination of pregabalin in human plasma using LC-MS-MS. Chromatographia. (2008) 67 (3): 237-43.
Nirogi R, Kandikere V, Mudigonda K, Komarneni P, Aleti R. Liquid chromatography atmospheric pressure chemical ionization tandem mass spectrometry method for the quantification of pregabalin in human plasma. J. Chromatogr. B. (2009) 877 (30): 3899-906.
Shah GR, Ghosh C, Thaker BT. Determination of pregabalin in human plasma by electrospray ionisation tandem mass spectroscopy. J. Adv. Pharm. Technol. Res. (2010) 1 (3): 354.
Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J. Clin. Pharmacol. (2010) 50 (8): 941-50.
Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther. Drug Monit. (2005) 27 (4): 451-6.
Vermeij T, Edelbroek P. Simultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection. J. Chromatogr. B. (2004) 810 (2): 297-303.
Wu T, Jing Q-F, Ye B, Shen Y-J. Determination of Pregabalin by HPLC with precolumn derivatization using 1-fluoro-2, 4-dinitrobenzene. Chin. J. Chem. Eng. (2010) 2: 350-3.
Ahmadkhaniha R, Mottaghi S, Zargarpoor M, Souri E. Validated HPLC method for quantification of pregabalin in human plasma using 1-Fluoro-2, 4-dinitrobenzene as derivatization agent. Chromatogr. Res. Int. (2014) 2014.
Shah J, Kotadiya R. A Critical review on analytical methods for recently approved fdc drugs: pregabalin and etoricoxib. Crit Rev Anal Chem. (2022) 52 (5): 1048-68.
Martinc B, Grabnar I, Mrhar A, Vovk T. Rapid high-performance liquid chromatography method for determination of pregabalin in a pharmaceutical dosage form following derivatization with fluorescamine. J. AOAC Int. (2010) 93 (4): 1069-76.
Walash M, Belal F, El‐Enany N, El‐Maghrabey MH. Simple and sensitive spectrofluorimetric method for the determination of pregabalin in capsules through derivatization with fluorescamine. Luminescence. (2011) 26 (5): 342-8.
Douša M, Gibala P, Lemr K. Liquid chromatographic separation of pregabalin and its possible impurities with fluorescence detection after postcolumn derivatization with o-phtaldialdehyde. J. Pharm. Biomed. Anal. (2010) 53 (3): 717-22.
Themelis DG, Tzanavaras PD, Boulimari EA. Generic automated fluorimetric assay for the quality control of gamma aminobutyric acid-analogue anti-epileptic drugs using sequential injection. Anal. Lett. (2010) 43 (6): 905-18.
Shaalan RA-A. Spectrofluorimetric and spectrophotometric determination of pregabalin in capsules and urine samples. Int. J. Biomed. Sci. (2010) 6 (3): 260.
Kostić N, Dotsikas Y, Malenović A. Critical review on the analytical methods for the determination of zwitterionic antiepileptic drugs—vigabatrin, pregabalin, and gabapentin—in bulk and formulations. Instrum. Sci. Technol. (2014) 42 (4): 486-512.
Radwan RA, Abouzied NF, Badway FA, HA H ammad, Hassan AM. New Method Development for Pregabalin Detection in Human Plasma by HPLC-DAD. 6(3)61-6 (2020).
Kritikos N, Iliou A, Kalampaliki AD, Gikas E, Kostakis IK, Michel BY, et al. chemometrically assisted optimization of pregabalin fluorescent derivatization reaction with a novel xanthone analogue and validation of the method for the determination of pregabalin in bulk via a plate reader. Molecules. (2022) 27 (6): 1954.
Derayea SM, Attia TZ, Elnady M. Development of spectrofluorimetric method for determination of certain antiepileptic drugs through condensation with ninhydrin and phenyl acetaldehyde. Spectrochim. Acta A Mol. Biomol. (2018) 204: 48-54.
Derayea SM, Attia TZ, El Nady M. The utility of acetylbutyrolactone for spectrofluorimetric determination of two gamma-aminobutyric acid analogues. J. biomed. pharm. sci. (2018) 1 (1): 6-12.
Abdel Hamid MA, Mabrouk MM, Ahmed HM, Samy B, Batakoushy HA. Carbon quantum dots as a sensitive fluorescent probe for quantitation of pregabalin; application to real samples and content uniformity test. Luminescence. (2022) 37 (1): 170-6.
Elbashir AA, Suliman FEO, Aboul-Enein HY. The application of 7-chloro-4-nitrobenzoxadiazole (NBD-Cl) for the analysis of pharmaceutical-bearing amine group using spectrophotometry and spectrofluorimetry techniques. Appl. Spectrosc. Rev. (2011) 46 (3): 222-41.
Önal A, Sagirli O. Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation. Spectrochim. Acta A Mol. Biomol. (2009) 72 (1): 68-71.
Walash MI, Belal FF, El-Enany NM, El-Maghrabey MH. Utility of certain nucleophilic aromatic substitution reactions for the assay of pregabalin in capsules. Chem. Cent. J. (2011) 5 (1): 1-10.
Nawab S, Nasreen F, Shahnaz P, Farhan AS, Alisha WS. Pregabalin and tranexamic acid evaluation by two simple and sensitive spectrophotometric methods. Int. J. Anal. Chem. (2015).
Alka B , Prateek G. A novel method for spectrophotometric determination of pregabalin in pure form and in capsules. BMC Chemistry. (2011) 5: 59.
Chafer-Pericas C, Campıns-Falcó P, Herraez-Hernandez R. Application of solid-phase microextraction combined with derivatization to the determination of amphetamines by liquid chromatography. Anal. Biochem. (2004) 333 (2): 328-35.
Zou QH, Xie MX, Wang XF, Liu Y, Wang J, Song J, et al. Determination of sulphonamides in animal tissues by high performance liquid chromatography with pre‐column derivatization of 9‐fluorenylmethyl chloroformate. J. Sep. Sci. (2007) 30 (16): 2647-55.
Chang X, Yu Z. Determination of etimicin in rat plasma using 9-fluorenylmethyl chloroformate precolumn derivatization by HPLC with fluorescence detection. J. Braz. Chem. Soc. (2011) 22: 1246-52.
Souri E, Eskandari M, Tehrani MB, Adib N, Ahmadkhaniha R. HPLC determination of pregabalin in bulk and pharmaceutical dosage forms after derivatization with 1-fluoro-2, 4-dinitrobenzene. Asian J. Chem. (2013) 25 (13): 7332.
- چکیده مشاهده شده: 62 بار
- IJPS_Volume19_Issue4_Pages350-359 (English) دانلود شده: 46 بار